Wednesday, November 17, 2021 Daily Archives

3M™ Polisher ST — The Next Frontier in Downstream Processing, a Frost & Sullivan White Paper

by

Advancements in next-generation therapies—Paving the way for novel bioprocessing solutions. Learn about 3M Polisher ST technology which utilizes a guanidinium-functionalized polyamide membrane protected by a Q functionalized non-woven material. This Frost & Sullivan whitepaper explains how the technology demonstrates the viability of replacing the depth filtration and anion exchange chromatography (AEX) steps to achieve a simplified and cost-effective process. The platform is designed to reduce process and product related impurities and offer robust performance across a wide range of process…

November 17, 2021

Analytical Ultracentrifugation for Profiling AAV Gene Therapies: Where Are We Now?

by

This webcast features: Yijun Huang, Scientific Fellow, WuXi Advanced Therapies Adenoassociated virus (AAV) is often the vector of choice for gene therapies due to their low immunogenicity, ability to promote long-term gene expression, and capsid tropism-dependent tissue specificity. Representing around 37% of the current advanced therapies market, there is an ongoing demand for robust quality lot release programs capable of supporting the large patient cohorts involved in clinical trials. Along with critical quality attributes such as titer, identity, and potency,…

November 17, 2021

Lonza to expand microbial services at Swiss facility

by

The expansion at its Visp, Switzerland facility will support increased capacity of development services targeting microbial-derived proteins, says Lonza. The expansion will see Swiss contract development manufacturing organization (CDMO) Lonza up its microbial development laboratories at its Visp site by 50% as part of the firm’s focus on increasing its microbial service offerings. The investment, of which financial details have not been disclosed, will include the installation of a pilot suite with a 50 L fermenter and downstream equipment to…

November 17, 2021

CBM: SK investment to fund next growth phase for ambitious CDMO

by

The Center for Breakthrough Medicines (CBM) has taken an undisclosed amount from Korean investment firm SK Inc in its latest push to become the world’s largest cell and gene CDMO. In early 2020, life science and real estate investment company MLP Ventures and the Discovery Labs set-up CBM through a 680,000 square-foot facility at a former GSK R&D campus in King of Prussia, Pennsylvania. At the time, Brian O’Neill, founder of the Discovery Labs, said through $1.2 billion of funding…

November 17, 2021

Inceptor snaps up Arranta plant in Florida

by

Inceptor Bio has acquired a clinical manufacturing plant in Gainesville from Arranta Bio to support trials of its cell therapy pipeline. The 29,000 square-foot facility will be used as a base for Inceptor’s Advanced Manufacturing Platform (AMP), a scalable shared production infrastructure used to produce a pipeline of cell therapy candidates for the firm and its subsidiaries. “We are thrilled to welcome the experienced, talented operating team from Arranta and look forward to establishing cell therapy GMP clinical manufacturing as…

November 17, 2021